French court rules against Sanofi in landmark Depakine case
Sanofi has faced a slew of allegations over the last several years that its epilepsy drug Depakine causes birth defects when taken during pregnancy. Last week, it suffered a stinging loss in a French court — but the pharma giant’s legal trouble is far from over.
A court in Nanterre — a city several miles outside of Paris — ruled last week that Sanofi must pay up to €450,000 in damages to a family whose child suffered a form of autism after exposure to Depakine, multiple sources reported. According to Reuters, plaintiffs alleged that Sanofi knew of the potential risks to pregnant women, and failed to notify patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
